StreetInsider.com News Articles

Neumora Therapeutics (NMRA) PT Lowered to $5 at RBC Capital

Mon, 13 Jul 2026 07:26:32 -0400

RBC Capital analyst Brian Abrahams lowered the price target on Neumora Therapeutics (NASDAQ: NMRA) to $5.00 (from $7.00) while maintaining a Outperform rating.

Neumora Therapeutics (NMRA) PT Lowered to $4 at Mizuho

Mon, 22 Jun 2026 06:46:24 -0400

(Updated - June 22, 2026 6:46 AM EDT)

Mizuho analyst Graig Suvannavejh lowered the price target on Neumora Therapeutics (NASDAQ: NMRA) to $4.00 (from $6.00) while maintaining a Outperform rating.

The analyst commented: "Following this week's announcement of negative P3 KOASTAL-2 and -3 study outcomes, and the removal of navacaprant for depression from our model, we lower our PT to $4. Though some may put NMRA in the penalty box for the negative P3 navacaprant readout, we remind of the co's remaining pipeline, one which, though early in nature, we find highly intriguing, with: (1) NMRA-511, a vasopressin 1a receptor/V1aR antagonist in

Neumora Therapeutics (NMRA) PT Lowered to $4 at Mizuho

Mon, 22 Jun 2026 06:46:24 -0400

(Updated - June 22, 2026 6:46 AM EDT)

Mizuho analyst Graig Suvannavejh lowered the price target on Neumora Therapeutics (NASDAQ: NMRA) to $4.00 (from $6.00) while maintaining a Outperform rating.

Neumora Therapeutics (NMRA) PT Lowered to $5 at Needham

Tue, 16 Jun 2026 07:13:10 -0400

(Updated - June 16, 2026 7:13 AM EDT)

Needham analyst Ami Fadia lowered the price target on Neumora Therapeutics (NASDAQ: NMRA) to $5.00 (from $8.00) while maintaining a Buy rating.

The analyst commented: "NMRA will be discontinuing navacaprant development following the KOASTAL-2/3 readout which, did not meet the PE (MADRS) or the key SE (SHAPS). While disappointing, we are removing navacaprant related sales and costs from our model and incorporating the 35% workforce reduction (right-sizing to a mid-stage biotech) announced today, which will drive $10M in annualized savings (mgt expects to hit run-rate in 2027). This lowered our PT from $8 to

Neumora Therapeutics (NMRA) PT Lowered to $5 at Needham

Tue, 16 Jun 2026 07:13:10 -0400

(Updated - June 16, 2026 7:13 AM EDT)

Needham analyst Ami Fadia lowered the price target on Neumora Therapeutics (NASDAQ: NMRA) to $5.00 (from $8.00) while maintaining a Buy rating.

Neumora Therapeutics (NMRA) PT Lowered to $7 at H.C. Wainwright

Tue, 16 Jun 2026 06:47:13 -0400

(Updated - June 16, 2026 6:47 AM EDT)

H.C. Wainwright analyst Douglas Tsao lowered the price target on Neumora Therapeutics (NASDAQ: NMRA) to $7.00 (from $18.00) while maintaining a Buy rating.

The analyst commented: "Yesterday, Neumora announced that the Phase 3 KOASTAL-2 and -3 studies of navacaprant for the treatment of major depressive disorder (MDD) did not meet the primary or key secondary endpoints and, as a result, the company is discontinuing development of the drug. The company will focus its attention on NMRA-898 (M4 PAM), NMRA-511 (V1a antagonist) and NMRA-215 (NRLP3 inhibitor). We were a bit surprised by the magnitude of

Neumora Therapeutics (NMRA) PT Lowered to $7 at H.C. Wainwright

Tue, 16 Jun 2026 06:47:13 -0400

(Updated - June 16, 2026 6:47 AM EDT)

H.C. Wainwright analyst Douglas Tsao lowered the price target on Neumora Therapeutics (NASDAQ: NMRA) to $7.00 (from $18.00) while maintaining a Buy rating.

Form 8-K Neumora Therapeutics, For: Jun 10

Mon, 15 Jun 2026 08:15:00 -0400

si-local-file:///var/storage/secattach/20260615/26644641.html

Form 8-K Neumora Therapeutics, For: Jun 10

Mon, 15 Jun 2026 08:15:00 -0400

si-local-file:///var/storage/secattach/20260615/26644641.html

Neumora Therapeutics (NMRA) Halted, News Pending

Mon, 15 Jun 2026 08:01:13 -0400

Neumora Therapeutics (NASDAQ: NMRA) Halted, News Pending

Neumora discontinues navacaprant after phase 3 trials fail primary endpoints

Mon, 15 Jun 2026 08:00:42 -0400

Neumora Therapeutics Inc. (NASDAQ: NMRA) announced that its phase 3 KOASTAL-2 and KOASTAL-3 studies of navacaprant for major depressive disorder failed to meet primary endpoints, prompting the company to discontinue development of the drug candidate.

The KOASTAL-2 study enrolled 430 patients, while KOASTAL-3 enrolled 422 patients. In KOASTAL-2, patients treated with navacaprant 80 mg showed similar improvement to placebo on the Montgomery-Åsberg Depression Rating Scale at week 6. In KOASTAL-3, navacaprant patients demonstrated numerically lower improvement than placebo patients.

Following the trial results, Neumora will reduce its workforce by approximately 35%, resulting in annualized cost savings of about $10 million. The company

Neumora discontinues navacaprant after phase 3 trials fail primary endpoints

Mon, 15 Jun 2026 08:00:42 -0400

Following the trial results, Neumora will reduce its workforce by approximately 35%, resulting in annualized cost savings of about $10 million. The company

Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update

Mon, 15 Jun 2026 08:00:00 -0400

Navacaprant did not achieve the primary endpoint in KOASTAL-2 or -3; Company to discontinue development of navacaprant

Advancing potential best-in-class programs with NMRA-511 in Alzheimer’s disease agitation, NMRA-898 in schizophrenia and NMRA-215 in cardiometabolic disease

Aligning organization to support initiation of multiple clinical studies, with cash runway into the third quarter of 2027

WATERTOWN, Mass., June 15, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases,

Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update

Mon, 15 Jun 2026 08:00:00 -0400

Navacaprant did not achieve the primary endpoint in KOASTAL-2 or -3; Company to discontinue development of navacaprant

Advancing potential best-in-class programs with NMRA-511 in Alzheimer’s disease agitation, NMRA-898 in schizophrenia and NMRA-215 in cardiometabolic disease

Aligning organization to support initiation of multiple clinical studies, with cash runway into the third quarter of 2027

Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update

Mon, 15 Jun 2026 08:00:00 -0400

Navacaprant did not achieve the primary endpoint in KOASTAL-2 or -3; Company to discontinue development of navacaprant

Advancing potential best-in-class programs with NMRA-511 in Alzheimer’s disease agitation, NMRA-898 in schizophrenia and NMRA-215 in cardiometabolic disease

Aligning organization to support initiation of multiple clinical studies, with cash runway into the third quarter of 2027

Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update

Mon, 15 Jun 2026 08:00:00 -0400

Navacaprant did not achieve the primary endpoint in KOASTAL-2 or -3; Company to discontinue development of navacaprant

Advancing potential best-in-class programs with NMRA-511 in Alzheimer’s disease agitation, NMRA-898 in schizophrenia and NMRA-215 in cardiometabolic disease

Aligning organization to support initiation of multiple clinical studies, with cash runway into the third quarter of 2027

Form 4 Neumora Therapeutics, For: May 27 Filed by: Burow Kristina

Fri, 29 May 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260529/26575836.html

Form 4 Neumora Therapeutics, For: May 27 Filed by: Burow Kristina

Fri, 29 May 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260529/26575836.html

Form 4 Neumora Therapeutics, For: May 27 Filed by: Fust Matthew K

Fri, 29 May 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260529/26575765.html

Form 4 Neumora Therapeutics, For: May 27 Filed by: Fust Matthew K

Fri, 29 May 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260529/26575765.html

Form 4 Neumora Therapeutics, For: May 27 Filed by: Piacquad David

Fri, 29 May 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260529/26575543.html

Form 4 Neumora Therapeutics, For: May 27 Filed by: Piacquad David

Fri, 29 May 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260529/26575543.html

Form 4 Neumora Therapeutics, For: May 27 Filed by: Halawa Alaa

Fri, 29 May 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260529/26575529.html

Form 4 Neumora Therapeutics, For: May 27 Filed by: Halawa Alaa

Fri, 29 May 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260529/26575529.html

Form 4 Neumora Therapeutics, For: May 27 Filed by: Ho Maykin

Fri, 29 May 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260529/26575515.html